
Sku: WE2618

Catalog No.: WE2670
Specification: 1mg/5mg/25mg/50mg/100mg
Stock: In stock
Product details, specifications, documents, and related products are available from the catalog record. Learn more
Background:PD-1/VEGF Bispesific Antibody is a novel cancer immunotherapy drug that can target both PD-1 and VEGF. It blocks the interaction between PD-1 and PD-L1/PD-L2. The bispecific antibody can specifically bind to VEGFA and PD-1, selectively relieve the immune suppression caused by VEGFA and PD-1 in the body, and inhibit tumor-induced angiogenesis.
ucallm
Datasheet, COA, SDS, and protocol files can be requested from technical support.
Emailinfo@mail.ucallm.com
Phone+(1)-866-986-9598
WeChat / IMUcallm-Tech
HoursMonday-Friday 09:00-18:00 CST